Louis et al. demonstrated risankizumab to significantly improve clinical remission rates compared to placebo in both an induction trial and in a maintenance trial for patients with moderately to severely active ulcerative colitis.

The authors assessed two phase 3 randomised clinical trials evaluating the efficacy and safety of risankizumab in treating moderately to severely active ulcerative colitis.

Keywords:


Publication thumbnail: Risankizumab for Ulcerative Colitis Two Randomized Clinical Trials
LinkedIn